Addressing on skilled talent, strong manufacturing capabilities and thriving research ecosystem in pharmaceutical firms to set up to serve patients and connect with the growing Asian market

• Drug pipeline growth areas
• Regulatory trends
• Innovation in pricing and market access
• The most significant industry trends in the long term, and how should Pharma respond

• Pricing and reimbursement governance
• Implementing best practices, policies and tools for enhanced pricing decisions in private and reimbursed markets
• Adapting market access strategies for growth regions (Japan, Korea & China markets) in Asia

• Understanding the current landscape in ANZ in light of reimbursement models and payer needs
• Effectively managing stakeholder expectations and aligning market strategies
• Utilizing HEOR to formulate effective pricing strategies

• Assessing the current landscape of Asia’s emerging markets and reimbursement policy
• Hot markets in spotlights
• Reviewing current pricing and reimbursement models – what works and what doesn’t work
• Aligning market access and pricing strategies with government policies and payer insights

• Overview of evidence-driven approach for strategic planning in Asia Pacific
• How HEOR/RWE can support pricing and market access in different product lifecycle?
• Leveraging retrospective and prospective real world data to strengthen product value communication with relevant stakeholders

• Design and implement cost-minimization and cost-effectiveness models to support local product adoption
• Implement clinical and economic studies to generate outcome data and support local reimbursement submissions
• Ensuring successful health economics, pricing and tender outcomes through strategic internal and external collaborations

• Due to the scarcity of patients and knowledge on rare diseases, orphan drugs often pose challenges to patients, payers, regulatory authorities and legislators.
• Also, when introducing a new drug, it is always important that the pharmaceutical company recognizes differences in access procedures by country, which are more complicated in orphan drugs.
• All the pharmaceutical companies who aim to benefit rare disease patients in the region need to understand the current state of the art surrounding the access procedures, which are progressing daily but still have many complications country by country.

• Fueling data-driven healthcare through big data & healthcare analytics
• Improving collaborations between pharma & insurers, in terms of data sharing to derive costs
• Consolidating real-world patient data for coverage decisions and value-based payments

• Current medical insurance and claims regulation landscape for patients in HK
• Factors affecting medical coverage of patients and costs involved
• Enabling affordability for patients and better long-term treatment options
• Better drugs for lesser side effects and the importance of preventive medicine

• Outside the traditional realm of drugs, many pharma companies are partnering with medical device and MedTech companies to formulate combination products
• Examining evolving models of integrated care, implication for pharma and healthcare providers
• Changing the way we approach market access for combination products, to capture value creation